Shares of Hims & Hers Health Inc. (HIMS) surged 5.06% in intraday trading on Friday, as investors cheered the company's potential for growth in the weight-loss drug market.
According to analysts at Canaccord Genuity, compounded versions of GLP-1 weight-loss drugs represent a high-growth revenue stream for telehealth firms like Hims & Hers in the near term. A survey conducted by the brokerage found that nearly half of the respondents interested in taking GLP-1 drugs were undecided between branded or compounded versions, leaving ample room for the compounded option to gain further adoption.
Notably, Hims & Hers was the most recognized telehealth platform among the survey respondents who expressed interest in using such a service to obtain GLP-1 treatment. The company's value proposition of providing affordable and easy access to medication and medical professionals aligns well with the key factors influencing respondents' selection of a telehealth platform.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。